A new approach to the synthesis of [(1-phenyl-3-trifluoromethylpyrazol-5-yl)oxy]-alkan-1-ols was developed via alkylation of 5-hydroxy-1-phenyl-3-trifluoromethylpyrazole with commercially available dibromoalkanes, followed by stepwise treatment of the resulting 5-bromoalkoxy-1-phenyl-3-trifluoromethylpyrazoles with silver acetate and sodium methoxide. It was shown that [(1-phenyl-3-trifluoromethylpyrazol-5-yl)oxy]alkan-1-ols exhibit low acute toxicity and high analgesic activity in the in vivo hot plate test, acting as partial agonists of the TRPV1 ion channel, as confirmed in vitro tests and by molecular docking. For the lead compound, pyrazole with a hydroxybutoxy substituent, moderate inhibitory activity against cyclooxygenase-2 was shown.